Atara Biotherapeutics (NASDAQ: ATRA) is a clinical-stage biopharmaceutical company focused on developing cell therapy product candidates. The company has not yet generated product revenue from approved therapies and funds operations through capital raises and, based on balance sheet line items visible in the FY2025 10-K, a liability related to the sale of future revenues. Headquartered in Thousand Oaks, California, Atara has undergone multiple rounds of workforce reductions, including cuts in August 2022 (approximately 20%), November 2023 (approximately 30%), January 2024 (approximately 25%), and additional reductions in January, March, May, and October 2025. AnhCo "Cokey" Nguyen was appointed President and Chief Executive Officer in September 2024, succeeding Pascal Touchon. The company operates research facilities including an ARC facility that was partially wound down in 2025, resulting in a $4.1 million right-of-use asset impairment and a subsequent $6.0 million lease liability gain recorded in FY2025.

Revenue model

Atara has no disclosed commercial product revenue in the filing excerpts. The balance sheet reflects a liability related to the sale of future revenues, indicating the company has monetized future potential royalties or milestone payments. Operating expenses are concentrated in research and development.

Products and services

Cell therapy product candidates in clinical development. No approved products are identified in the filing excerpts. The ARC facility supported research and development activities and was partially wound down in 2025.

Customers and end markets

No commercial customers are identified in the filing excerpts. The company targets therapeutic end markets requiring regulatory approval from bodies including the FDA, EMA, and MHRA before any commercial sales can occur.

Value-chain role

Clinical-stage drug developer relying on third-party contract manufacturers and service providers. The company conducts its own research and development and manages clinical studies internally, with dependence on third-party IT and operational infrastructure.

Geographic exposure

Headquartered in Thousand Oaks, California. Regulatory filings reference the United States, the European Economic Area, and the United Kingdom as target markets for potential future commercialization.

Source: SEC 10-K, filed 2026-03-16

Industry: Biological Products, (No Diagnostic Substances) Peers: BioXcel Therapeutics Inc Kalvista Pharmaceuticals Inc Eiger BioPharmaceuticals, Inc. Foghorn Therapeutics Inc Karyopharm Therapeutics Inc Prelude Therapeutics Inc Scholar Rock Holding Corp Vigil Neuroscience, Inc. Tyra Biosciences Inc